Ye 2007.

Study characteristics
Methods	RCT, single centre, 40 participants, 20 months' duration
Participants	40 enrolled: CHM = 20, control 1 = 10, control 2 = 10, baseline were comparable, 27.4 ± 2.7 years 40 analysed/evaluated: CHM = 20, control 1 = 10, control 2 = 10 PCOS DC: 2003 Rotterdam criteria In: PCOS and infertility and resistance to ovulation induction drugs Ex: tubal infertility, male infertility, malformation of genital organ, immunological infertility
Interventions	CHM: CHM periodic therapy combined with laparoscopic ovary drilling Control 1: clomiphene combined with laparoscopic ovary drilling Control 2: laparoscopic ovary drilling Duration: treatment: 6 months, follow‐up: 1 year Clomiphene: 50 mg, once a day, 5 d/m (if without efficacy, add 50 mg, maximum 150 mg/d)
Outcomes	LH, FSH, testosterone Ovulation rate (per woman) Pregnancy rate (per woman)
Notes	Laparoscopic ovary drilling: 8 to 10 holes per ovary, injected 300 mL of low molecular dextran or 4 mL of sodium hyaluronate in abdomen after surgery.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	We contacted the study author who declined to provide related information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	We contacted the study author who declined to provide related information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	We contacted the study author who declined to provide related information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No withdrawal or dropout was reported
Selective reporting (reporting bias)	Unclear risk	The study protocol was unavailable
Other bias	Low risk	No other potential risk of bias identified

Abbreviations: CHM: Chinese herbal medicine, BMI: body mass index, PCOS: polycystic ovarian syndrome, DC: diagnosis criteria, In: inclusion criteria, Ex: exclusion criteria, HCG: human chorionic gonadotrophin, HMG: human menopausal gonadotropin, LH: luteinising hormone, FSH: follicle stimulating hormone, LUFS: luteinised unruptured follicle syndrome, OHSS: ovarian hyperstimulation syndrome, ITT: intention‐to‐treat, MPA: medroxyprogesterone acetate, EE/CPA: ethinyloestradiol cyproterone acetate, tid:three times a day, bid: twice a day, IU:International Units.